ACADIA Pharmaceuticals stock has delivered a 20.5% return over the past year, yet on current checks it still screens as undervalued, which raises the question of whether the recent move has fully reflected the news momentum around its pipeline.

• Over the last 12 months, ACADIA Pharmaceuticals is up 20.5%, suggesting investors are pricing in better prospects than were implied a year ago.
• The recent positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on Daybu for Rett syndrome can support higher growth expectations, while regulatory and commercial execution risks around that same therapy may limit how far the valuation can stretch.
• Across Simply Wall St’s broader checks, ACADIA Pharmaceuticals looks cheap on 5 of 6 valuation tests, meaning the stock currently leans toward undervalued territory rather than expensive on a cross check basis 5.

The issue now is whether ACADIA Pharmaceuticals’ recent gains already capture most of that apparent discount, or if there is still room for the valuation to close the gap suggested by those checks.

Is ACADIA Pharmaceuticals Still Cheap on Earnings?

The P/E ratio is a useful yardstick for ACADIA Pharmaceuticals because the company currently generates positive earnings that can be compared with peers and sector averages.

ACADIA Pharmaceuticals trades on a P/E of 11.9x, which sits well below the broader biotech industry average of 17.5x and the peer group average of 62.1x. Based on Simply Wall St’s fair P/E estimate of 19.0x, which adjusts for the company’s profile and risk factors, the stock is priced at a discount to what that framework suggests might be reasonable. The gap between the current and fair multiple indicates investors are not assigning the same valuation as the wider peer set.

Despite the recent CHMP recommendation for Daybu improving sentiment around ACADIA Pharmaceuticals, the current earnings multiple still implies a discounted valuation compared with both industry norms and the tailored fair P/E level.

On the P/E multiple alone, ACADIA Pharmaceuticals stock currently screens as undervalued compared with both its industry and a more tailored fair value benchmark.

The ACADIA Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take the valuation puzzle around ACADIA Pharmaceuticals' current P/E and turn it into a set of clear, testable assumptions about future growth, margins and earnings that would need to play out for the stock to be worth materially more or less than today's price. These Narratives are available on the company's Community page. Instead of stopping at a single output from a ratio or model, these Narratives unpack the future conditions that figure relies on so you can monitor whether those conditions actually occur over time.

Community views on ACADIA Pharmaceuticals sit far apart, with one camp focused on underappreciated specialization and another fixated on concentration and policy risk.

Bull case: 10% undervalued

"ACADIA’s strategy suggests it’s trying to evolve from a binary biotech story into a more durable specialty pharma model, one rooted in long-term patient management rather than episodic prescribing…"

Bear case: 32% overvalued

"ACADIA remains heavily dependent on a narrow product portfolio dominated by NUPLAZID and DAYBUE, leaving the company acutely exposed to patent cliffs, competitive threats from generics or biosimilars, and loss of exclusivity events after 2038…"

Do you think there's more to the story for ACADIA Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

For ACADIA Pharmaceuticals, the current picture is that the stock still screens as undervalued on market multiples, even after the recent move and positive news around its pipeline. The key question is whether that discount reflects lingering concerns about concentration in a few therapies and execution risk, or whether the market is underestimating the durability of its specialty pharma approach. From here, what matters most is whether ACADIA Pharmaceuticals can turn its pipeline and existing products into a broader, more resilient earnings base that eventually justifies a higher, peer like multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.